Decrease of Anti-DSG3, but Not Anti-DSG1 Antibody, After Cessation of Sitagliptin Treatment in a Patient With Pemphigus Vulgaris

JAMA Dermatol. 2019 Mar 1;155(3):391-393. doi: 10.1001/jamadermatol.2018.5379.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Autoantibodies / blood
  • Desmoglein 1 / blood
  • Desmoglein 1 / immunology*
  • Desmoglein 3 / blood
  • Desmoglein 3 / immunology*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / immunology
  • Drug Eruptions / etiology*
  • Drug Eruptions / physiopathology
  • Follow-Up Studies
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Middle Aged
  • Monitoring, Physiologic / methods
  • Pemphigus / chemically induced*
  • Pemphigus / immunology
  • Recurrence
  • Risk Assessment
  • Sitagliptin Phosphate / adverse effects*
  • Sitagliptin Phosphate / therapeutic use
  • Time Factors
  • Withholding Treatment

Substances

  • Autoantibodies
  • Desmoglein 1
  • Desmoglein 3
  • Hypoglycemic Agents
  • Sitagliptin Phosphate